Business Wire

FoodChain ID and IDFL Announce Strategic Worldwide Partnership to Advance Regenerative Agriculture and Certifications in the Textile Industry

28.10.2025 13:00:00 CET | Business Wire | Press Release

Share

FoodChain ID and IDFL today announced a strategic worldwide partnership that unites leading expertise to strengthen transparency from farm to finished product in the textile industry. The collaboration combines FoodChain ID’s agricultural certifications with IDFL’s textile certifications and testing, offering brands a seamless pathway to verify regenerative agricultural practices alongside textile chain-of-custody, social accountability, chemical compliance, environmental performance and animal welfare.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028455185/en/

The FoodChain ID and IDFL partnership allows brands to link on-farm regenerative outcomes with credible textile chain-of-custody and quality claims.

“By aligning FoodChain ID’s Regenerative Agriculture Certification with IDFL’s textile certification and testing capabilities, we’re making it easier for companies to implement credible sustainability programs across their entire textile value chain,” said Dr. Chetan Parmar, Senior Vice President of Technical Services for Europe and Asia. “Together, we will help brands accelerate progress toward transparent and responsible products.”

“IDFL’s global auditing and laboratory network, accredited to ISO/IEC 17065 and ISO/IEC 17025 and authorized by Textile Exchange and GOTS, positions us to deliver rigorous, scalable services for customers everywhere,” said Wilf Lieber, CEO at IDFL. “Partnering with FoodChain ID expands access to regenerative agriculture certification and strengthens textile sustainability outcomes.”

Partnership Highlights

  • Full Certification Services: Integrated certification across the supply chain, enabling continuous verification from raw material production to finished goods.
  • Global Coverage: Joint certification delivery through IDFL’s and FoodChain ID’s global certification and laboratory network.
  • Operational Excellence: Mutual commitments to maintain accreditations/authorizations, uphold impartiality and confidentiality, and ensure robust quality control over audits and certifications.

The partnership allows brands to link on-farm regenerative outcomes with credible textile chain-of-custody and quality claims. FoodChain ID will offer its Regenerative Agriculture Standard (ISO/IEC 17065–based) within the textile industry, while IDFL provides inspections, testing and certification to leading global textile standards, including GOTS, Responsible Down Standard (RDS), Responsible Wool Standard (RWS), Global Recycled Standard (GRS) and the Organic Content Standard (OCS).

About FoodChain ID

FoodChain ID is a trusted provider to over 30,000 companies across the global supply chain. The company delivers technology-enabled solutions and technical expertise to keep the food supply chain safe, compliant and transparent. Service areas include product development, regulatory compliance, food safety certification, product certification and testing. Learn more at www.FoodChainID.com.

About IDFL

Based in Salt Lake City, Utah, IDFL is the world’s leading testing and certification body for home textiles, apparel, and outerwear, specializing in quality assurance for natural and synthetic materials like down, feathers and polyester. Accredited to ISO/IEC 17065 and ISO/IEC 17025 and authorized by Textile Exchange and GOTS, IDFL operates laboratories and audit offices across Europe, Asia, and the Americas, providing comprehensive testing, inspections, audits, certifications, consulting, and training. Learn more at www.IDFL.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028455185/en/

Contacts

Media Contacts

Ceci Snyder
FoodChain ID
csnyder@foodchainid.com
+1 515-491-5173

Sam Arrington
IDFL
Sam.arrington@idfl.com
+1 801-467-7611

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye